ArticleCancers2020

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.

Desirée Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.